Skip to content
Menu

Sana Biotechnology, Inc. SANA

Full chart Compare
Set alert

Price alert · SANA

All alert types
1.74 USD -0.11 (-5.95%)

Regular-session close

1.74 0.00 0.00%

After hours · Nov 19, 4:18 PM ET

1.70 Day range 1.89
1.70 52-week range 5.49
YTD
-57.25%
1 year
-48.82%

5D -0.52 (-21.40%)

22.202.40TueWedThuFriMon1.91
Market cap
521.36M
EPS (ttm)
-0.52
Shares out
299.36M
Forward P/E
-6.21
YTD return
-57.25%
1-year return
-48.82%
50-day average
3.61
200-day average
3.70
Volume
3.99M
Avg volume
3.26M
Open
1.85
Previous close
1.85
Day's range
1.70 – 1.89
52-week range
1.70 – 5.49
Beta
2.13
Price target
8.43 (+384.4%)

Key statistics

Enterprise value
1.07B
Price / book
6.69
Free cash flow
4.13M
Total cash
160.49M
Total debt
80.94M
Return on equity
-152.87%
Short % of float
24.00%

Fundamental scorecard

4 of 25 checks passed on SANA’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SANA Revenue — quarterly 0
SANA Net income — quarterly 20.40M
SANA EPS — quarterly 0.07

Earnings

SANA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.18———
Aug 11, 2026Jun 30, 2026-0.1469-0.22-0.07-49.76%
May 11, 2026Mar 31, 2026-0.15-0.14+0.01+6.67%
Mar 3, 2026Dec 31, 2025-0.13-0.16-0.03-23.08%
Nov 6, 2025Sep 30, 2025-0.18-0.15+0.03+16.67%
Aug 11, 2025Jun 30, 2025-0.20-0.39-0.19-95.00%

Upgrades / downgrades

SANA analyst upgrades and downgrades
DateFirmActionFromTo
Aug 14, 2026B of A SecuritiesmainBuyBuy
Apr 14, 2026WedbushmainOutperformOutperform
Mar 4, 2026HC Wainwright & Co.mainBuyBuy
Jan 6, 2026B of A SecuritiesmainBuyBuy
Nov 7, 2025WedbushmainOutperformOutperform
Nov 7, 2025HC Wainwright & Co.mainBuyBuy

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
sana.com

News

Your note

Sign in to keep a note on SANA — it syncs with the Stock Master app.

Insider holders

SANA insider holders
InsiderRelationLatest transactionDateShares held
BISHOP HANS EDGARDirectorStock Award(Grant)Jul 5, 20265,854,800
CASSIDY BERNARD JGeneral CounselConversion of Exercise of derivative securityMar 6, 2025112,990
FMR LLCBeneficial Owner of more than 10% of a Class of SecuritySaleJan 7, 20250
HARR STEVE M.D.Chief Executive OfficerConversion of Exercise of derivative securityMar 5, 20268,960,750
MULLIGAN RICHARD CHARLES PH.DDirectorSaleSep 24, 20242,698,120
WYRICK SUSAN DOfficerConversion of Exercise of derivative securityMar 5, 2026196,196

Institution ownership

SANA institution ownership
Holder% heldSharesValueReported
FMR, LLC12.50%37,429,515129.13MJun 29, 2026
Flagship Pioneering LLC8.35%25,001,85686.26MJun 29, 2026
RA Capital Management, L.P.6.26%18,750,00064.69MJun 29, 2026
Blackrock Inc.5.57%16,675,17357.53MJun 29, 2026
State Street Corporation3.74%11,203,13438.65MJun 29, 2026
Canada Pension Plan Investment Board3.41%10,218,40035.25MJun 29, 2026

Fund ownership

SANA fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund3.51%10,495,61736.21MJul 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.36%7,077,51724.42MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.09%6,251,64421.57MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.61%4,807,95916.59MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1.04%3,119,05910.76MJul 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund0.95%2,857,7009.86MJul 30, 2026